Product
ligelizumab
1 clinical trial
1 indication
Indication
AllergyClinical trial
A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut AllergyStatus: Terminated, Estimated PCD: 2023-08-11